#microarray

Common uses of bioinformatics

💡Sequence analysis Analyzing DNA and protein sequences to identify genes, regulatory regions & mutations.

💡Gene expression Analyzing RNA expression data from experiments like microarrays or RNA-seq to understand gene regulation.

💡Phylogenetics Constructing evolutionary relationships between organisms based on genetic data and genomic comparisons.

💡Molecular modeling Predicting protein structure and docking drugs to proteins using computational modeling and simulation.

💡Databases & Data mining Developing databases like GenBank to store biological data and mining it to find patterns.

💡Genomics Studying entire genomes, including sequencing and assembling genomes as well as identifying genes and genomic variations.

𝐌𝐢𝐜𝐫𝐨𝐚𝐫𝐫𝐚𝐲 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲

🔬 Microarray Chromosomes Analysis Test 🧬

Accurately detects microdeletions and duplications, providing essential insights for genetic disorders and personalized treatment options! 🌟

📞 +91 9900811118

Trisomy 21 (Down syndrome), trisomy 18 (Edward's syndrome), and trisomy 13 (Patau's syndrome) are the three most prevalent autosomal aneuploid diseases. The incidence in newborns is 1/(600-800), 1/(3500-8000), and 1/(7000-20000). Intellectual disability, developmental delay, multiple deformities, reproductive disorders, etc. are common in children.

Using a fetal chromosome aneuploidy (T21, T18, T13) detection kit (semiconductor sequencing), doctors can reliably identify these conditions in unborn children (trisomy 21, trisomy 18, and trisomy 13).

Features of Fetal Aneuploidies (Trisomy 21, Trisomy 18, and Trisomy 13) Detection

According to data from 190,277 NIPT clinical trials

Once proven effective in clinical studies【1】: in total, NIPT has a sensitivity of 99.61% for T21, T18, and T13 and a specificity of 99.91%. Overall PPV was 89.74% and NPV was 99.99%.

Test Type

Sensitivity

Specificity

Positive predictive value

Negative predictive value

Trisomy 21

99.80%

99.98%

96.42%

100.00%

Trisomy 18

98.84%

99.98%

87.08%

100.00%

Trisomy 13

100%

99.96%

32.08%

100%

Total

99.61%

99.91%

89.74%

100.00%

The concentration of fetal cell-free DNA is raised from 11.3% to 22.6% through novel experimental techniques.[1] Hu H, Liu H, Peng C, et al. Clinical Experience of Non-Invasive Prenatal Chromosomal Aneuploidy Testing in 190,277 Patient Samples[J]. Current Molecular Medicine, 2016, 16(8)：759-766

Workflow of Fetal Aneuploidies (Trisomy 21, Trisomy 18 and Trisomy 13) Detection

Workflow of Fetal Aneuploidies (Trisomy 21, Trisomy 18 and Trisomy 13) Detection

Target Population of Fetal Aneuploidies (Trisomy 21, Trisomy 18 and Trisomy 13) Detection

Women who are pregnant and whose fetal chromosomal aneuploidy risk value on a serological screen is between the high-risk cut-off value and 1/1000;

Those who cannot undergo interventional prenatal diagnosis due to certain conditions (such as a history of abortion, a current infection with a chronic pathogen, a blood type other than Rh-positive, etc.);

Patients who consult after 20+6 weeks of pregnancy have missed the optimal window for serological screening, but still need an assessment of their risk for trisomy 21, trisomy 18, and trisomy 13.

Specification of Fetal Aneuploidies (Trisomy 21, Trisomy 18 and Trisomy 13) Detection

Order information

Cat. No.

Description

Specification

S30030

Fetal Aneuploidies (Trisomy 21, Trisomy 18, and Trisomy 13) Detection Kit (Semiconductor Sequencing)

160 tests/kit

S10020

Nucleic Acid Extraction/Purification Kit

96 tests/kit

S10010

Sequencing Reaction Universal Kit (Semiconductor Sequencing)